SC
EW icon

Seldon Capital’s Edwards Lifesciences EW Stock Holding History

Seldon Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-459
Closed -$34.2K – 125
2022
Q4 		$34.2K Hold
459
– – 0.03% 165
2022
Q3 		$38K Hold
459
– – 0.03% 158
2022
Q2 		$44K Hold
459
– – 0.03% 153
2022
Q1 		$54K Hold
459
– – 0.03% 152
2021
Q4 		$59K Buy
+459
New +$53.5K 0.04% 150

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Seldon Capital's EW Position: Q1 2023 in Review

Seldon Capital sold out of Edwards Lifesciences (EW) in Q1 2023, closing a stake of 459 shares — an estimated $34.2K sold.

Seldon Capital first reported a position in EW in Q4 2021 and held it in 5 quarters. The position peaked at $59K in Q4 2021. 1,245 funds tracked by Wall St. Rank hold EW as of Q1 2023.

  • Seldon Capital reported no remaining Edwards Lifesciences position as of Q1 2023 after selling out during the quarter.
  • Seldon Capital sold 459 Edwards Lifesciences shares in Q1 2023, an estimated $34.2K.
  • Seldon Capital first reported a position in Edwards Lifesciences in Q4 2021 and held it in 5 quarters.
  • Seldon Capital's Edwards Lifesciences position peaked at $59K in Q4 2021.
  • 1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2023.

Based on Seldon Capital's 13F filing for Q1 2023, filed 12 May 2023.